ALPHA TAU MEDICAL LTD

Alpha Tau Medical’s latest stock update shows a 2% rise, $13.16 price, and $1.2 billion market cap—deep dive into its alpha‑emitter radiation therapy growth potential.

Alpha Tau Medical’s new Samsung partnership looks promising but remains speculative—no regulatory approval yet, and the company’s pre‑clinical alpha‑emitter therapy carries high risk.

Alpha Tau Medical’s steady climb above its 200‑day SMA signals a bullish trend, with a promising clinical pipeline and FDA‑favorable outlook that could lift the stock toward its 52‑week high.